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BAL17 cells pulsed with goat antl-IgM or anti-IgD as antigens stimulated a goat IgG specific T cell clone in terms of mositol phosphate production. 
The antigen-presentmg capacity of BALI7 cells was inhibited by pretreatment with the tyrosine kinase inlubitors herbimycin A or gemstein. 
Furthermore, ligand-induced cappmg and endocytosis of membrane lmmunoglobulin. monitored at the single cell level, was also blocked by 
herbimycin A. These results indicate that tyrosme phosphorylation plays an important role in receptor-mediated antigen presentation by B cells. 
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1. INTRODUCTION 
B cells take up antigens via pinocytosis or receptor- 
mediated events, one of which is an immunoglobulin 
(mlg)-induced step. The internalized antigen is proc- 
essed and presented to T cells, which then become acti- 
vated [1,2]. The mlg-mediated uptake of an antigen is 
far more efficient than pinocytosis and is considered to 
play an essential role in antibody response through a 
collaboration between B cells and T cells [ 1,2]. 
Ligation of mIg stimulates B cells to activate tyrosine 
phosphorylation of several proteins including phospho- 
lipase C (PLC) [3-61. The activation of PLC has been 
shown to be associated with the activation of the en- 
zyme leading to generation of inositol triphosphate and 
diacylglycerol through phosphatidylinositol breakdown 
[5-71. Inositol triphosphate increases the levels of intra- 
cellular calcium and diacylglycerol activates protein ki- 
nase C [7,8]. B cells contain at least three species of 
tyrosine kinase, namely fyn, lyn, and blk, which are 
associated with mIgM or mIgD [9-121. These kinases 
are phosphorylated at a tyrosine residue after mIg 
cross-linking, which probably correlates with the activa- 
tion of the enzyme and controls the critical early events 
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in B cell activation [l l-141. Using tyrosine kinase inhib- 
itors, we examine the effect of tyrosine kinase on the 
capacity of B cells to present the antigen taken up 
through mIg to T cells. We show that tyrosine kinase 
participates in antigen-presentation by B cells and that 
at least antigen-uptake involves the activation of tyro- 
sine kinases. 
2. MATERIALS AND METHODS 
2 1. Cells und ontihodres 
BAL17 B lymphoma cells were maintained m culture me&urn con- 
taining RPMI-1640 supplemented with 10% fetal calf serum, 2 mM 
glutamme, lOO~g/ml kanamycm. and 50pM 2-mercaptoethanol. Pre- 
treatment of BALI7 cells with herblmycm A (a gift from Yoshimasa 
Uehara. National Institute of Health. Japan) was carried out as previ- 
ously described [6]. A goat IgG-specific T cell clone, 52-3D, was 
established from BALB/c mice immunized with goat IgG as previously 
described [15]. Normal goat IgG &as purified from normal goat sera 
by a combination of 50% saturated ammomum sulfate precipitation 
and a DE 52 column (Whatman Ltd). Goat anti-mouse IgM H chain- 
specific antibody (anti-IgM) was prepared as described [6]. Goat anti- 
mouse IgD (anti-IgD) was a gift from Fred Finkelman (Uniformed 
Services University of Health Sciences, Bethesda, MD). Gemstein was 
from Calblochem Biochemicals (San DIego, CA). 
2.2. Itrosltol phosphate production 
Accumulation of inositol phosphate was measured by the method 
described previously [16]. 
2.3. Cappmg and Internalization 
Cells (3 x 105) were attached to a glass slide using Auto-Smear 
(Hitachi Co.) and stimulated with 5 &ml of FITC-labeled anti-IgM 
(FITC-anti-IgM) on Ice. After washing, cells were set m an interactive 
laser cytometer (ACAS 570, Meridian Instrument Inc.) and fluores- 
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Fig. 1. Herbimycin A inhibits anti-IgM-induced capping of mIg in a single BAL17 cell, BAL17 cells pretreated without (a) or with (b) 1 ,uM of 
herbimycin A were stimulated with FITC-anti-IgM on cover shps. A representative single cell was monnored for 60 mm 
cence was traced every 15 mm at 37°C for 60 mm. The mternalization 
of FITC-anti-IgM was observed using an ACAS 570 confocal system 
with a pin-hole of 40 pm. This confocal imagmg sigmlicantly reduces 
out-of-focus light usmg a dtffraction hmited opttcus and placmg a pin 
hole m front of the detector to allow only light from the plane of focus 
to be detected. 
Table I 
Herbimycm A or genistein mhibits the capacity of BAL17 B lym- 
phoma cells to present anti-IgM or anti-IgD to a goat IgG-specific T 
cell clone 
Antigen Pretreatment Accumulation of 
mositol phosphates 
(cpm/culture) 
Espt I 
None 
Anti-IgM 
Anti-IgD 
- 72 
+ 89 
_ I .084 
+ 81 
_ 720 
+ 76 
E.yt 2 
None 
Anti-IgM 
- 88 
t 143 
_ 3,480 
+ 409 
BALI7 B lymphoma cells were pretreated with 1 ,uM herbimycm A 
for 12 h (Expt. 1) or 60 &ml gemstem for 3 h (Expt 2) with the 
addition of 1 &ml of anti-IgM or anti-IgD antibody for the final 3 
h. The cells were washed twice with RPMI-1640 and incubated with 
the [‘Hlmositol-labeled T cell clone for 40 mm The reaction was 
stopped by the addition of chloroform/methanol lnosttol phosphate 
production was measured as described m section 2 
3. RESULTS AND DISCUSSION 
We evaluated the role of tyrosine kinase on the capac- 
ity of B cells to present an antigen to T cells using the 
tyrosine kinase inhibitors herbimycin A and genistein 
[ 17,181. Anti-IgM or anti-IgD was used to stimulate B 
cells since these antigens were efficiently taken up 
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Fig. 2. Fluorescence Intensity of a single BAL17 cell pretreated with 
or without herbimycin A after FITC-anti-IgM stimulation. The fluo- 
rescence intensity of a BALI 7 cell treated as in Fig. 1 was momtored 
for 60 min. 
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through mIg by BAL17 B lymphoma cells bearing mIg 
and class II molecule. BAL17 cells pulsed with 1 ,ug/ml 
anti-IgM or anti-IgD antibody for 3 h caused an in- 
crease in inositol phosphate production in a goat IgG- 
specific T cell clone (Table I). As a control it was shown 
that goat IgG at 1 ,ug/ml could not be presented to T 
cells (data not shown). When BAL17 cells were pre- 
treated with 1 ,uM herbimycin A for 12 h or 60 &ml 
genistein for 3 h, the ability of the BAL17 cells to pres- 
ent the antigen was markedly blocked (Table I). 
B cells take up an antigen and process it. The peptide 
generated binds to major histocompatibility complex 
(MHC) class II molecules where it is recognized by T 
cells in the context of the MHC molecule [1,2]. Tyrosine 
kinase inhibitors are thought to inhibit at least one of 
these events. As a first step in analyzing the role of 
tyrosine kinase on these events, we examined whether 
inhibitors affect the anti-Ig-mediated capping or inter- 
nalization of mIg. BAL17 cells were incubated with 
FITC-anti-IgM at 37°C for 60 min using ACAS 570, 
which allows monitoring the fate of FITC-anti-IgM at 
the single cell level. Significant capping was observed at 
15 min and became more prominent at 45 min after 
FITC-anti-IgM stimulation (Fig. 1). Pretreatment with 
herbimycin A (1 ,uM) or genistein (30 ,&ml) markedly 
inhibited the capping. The extent of capping was quan- 
titated by measuring the relative fluorescence intensity 
around the capped area. Complete inhibition of capping 
is observed over the 60 min so far examined (Fig. 2). 
The dose-effect of the inhibitor was examined. As 
shown in Fig. 3, herbimycin A at 0.3 PM significantly 
inhibited the capping with approximately 90% inhibi- 
tion observed at 1 ,uM; complete inhibition (more than 
95%) was achieved at 3 PM. The profile of this dose- 
effect is quite similar to that of the sensitivity to anti-Ig- 
0 1 2 3 
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Fig. 3. Dose-response of herbimycm A-mediated inhibition on anti- 
IgM-induced capping. BAL17 cells pretreated with or without various 
concentrations of herbimycin A for 12 h were stimulated with FITC- 
anti-IgM for 50 min. Percentage of cells forming caps was calculated 
as follows: (cell number forming caps/total cell number) x 100; more 
than 100 BAL17 cells were exammed. Identical results were obtained 
in two other experiments. 
t 1 e t- t3 i m 3’ c i n A Control 
Fig. 4. Herbimycin A inhibition of anti-IgM-induced endocytosis. 
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induced inositol phospholipid metabolism, as reported 
previously [6]. This kinase inhibitor-mediated suppres- 
sion of capping was also observed using ‘?-labeled 
goat anti-IgM antibody (data not shown). To check the 
anti-IgM-mediated internalization accurately. we used 
ACAS 570 under confocal conditions. As shown in Fig. 
4, significant fluorescence from the inside of FITC-anti- 
IgM-treated BALI7 cells was observed, whereas no 
fluorescence was observed inside the herbimycin A-pre- 
treated cells. This indicates that tyrosine kinase partici- 
pates in anti-&-mediated internalization. 
The present results indicate that tyrosine kinase is 
involved in the capacity of B lymphoma cells to present 
antigen to T cells, partly because of the participation of 
the kinase in mIg-mediated internalization events. 
These findings support the recent report using conven- 
tional microscopy that the kinase inhibitor tyrphostin 
inhibits anti-Ig-mediated endocytosis in normal resting 
B cells [19]. We and others have demonstrated that 
several proteins are phosphorylated after receptor 
cross-linkage of mIg in BAL17 cells [6,12]. The dose 
response profile for the herbimycin A-mediated inhibi- 
tion of anti-IgM-induced tyrosine phosphorylation is 
similar to that for anti-IgM-induced capping. B cells 
have been shown to display at least three src-related 
tyrosine kinases [9-l 11, one of which might participate 
in these processes. Interestingly, the p53’?” protein is 
down-regulated after anti-Ig stimulation while ~56’)” 
content remains unchanged in B lymphoma cells (121. 
Down-regulation of the kinase might be accompanied 
by down-modulation of mIg through a phosphorylation 
event. ACAS may provide a valuable tool with which 
to monitor the regulation by tyrosine kinase of the cap- 
ping or internalization of mIg at the single cell level. 
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